

2024年12月7日

D. Boral Capital による当社レポートの発表に関するお知らせ

現地時間の12月6日、米国ニューヨークに本拠を置く投資銀行D. Boral Capital のアナリストである Jason Kolbert 氏による、当社レポートが発表されましたので、参考情報としてお知らせいたします。

なお、当該レポートは、恐れ入りますが、権利の都合上、英文のままのご案内となりますので、ご了承ください。

【D. Boral Capital 公式 web サイト】

<https://dboralcapital.com/>

※当該レポートは、本書の下部にありますので、スクロールしてご確認ください。

MediciNova, Inc. (メディシノバ・インク)
東京事務所 IR 担当

E-mail infojapan@medicinova.com

URL <https://medicinova.jp/>

December 6, 2024

MediciNova Highlights Positive Interim Analysis from Phase 2/3 COMBAT-ALS Trial of MN-166

MediciNova announced an interim analysis update from its COMBAT-ALS Phase 2b/3 clinical trial evaluating MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). Presented at the 35th International Symposium on ALS/MND, the analysis revealed positive correlations between six- and twelve-month functional and survival metrics, supporting the robustness of the trial design. With over 200 patients enrolled, MediciNova anticipates completing assignments by mid-2025, with final results projected for 2026. This progress underscores MN-166's potential as a treatment for ALS and its broader implications for other neurodegenerative diseases.

The interim analysis of the COMBAT-ALS trial demonstrated a strong correlation between six- and twelve-month Combined Assessment of Function and Survival (CAFS) scores (0.71) and related functional metrics, including bulbar, fine motor, and gross motor subscores. These findings validate the 12-month double-blind trial design and provide confidence in MN-166's potential efficacy in ALS. The analysis was independently reviewed by a Data Safety Monitoring Board (DSMB), which endorsed the continuation of the trial as planned. MediciNova's decision to maintain the current treatment regimen reflects the company's commitment to generating robust, clinically meaningful data for regulatory submission.

Beyond the ongoing clinical trial, MediciNova has expanded patient access to MN-166 through the FDA's Expanded Access Program (EAP), offering continued treatment for eligible patients post-trial. The company is also preparing for a large-scale, NIH-funded EAP trial slated to commence next year. This dual approach not only accelerates patient access but also complements the primary COMBAT-ALS study by broadening real-world evidence for MN-166. These initiatives highlight MediciNova's proactive strategy to address the urgent need for ALS therapies while positioning MN-166 as a potential cornerstone in neurodegenerative disease management.

Valuation: For the purpose of our model we value MN-166 in ALS. We apply a probability of success factor of 30% based on the fact that its in pivotal trial. In addition, we have selected a 30% discount rate (r) for our forecasting models. We assume additional capital will be raised in our final share count. We then apply these projections to our Free Cash Flow to the firm, or FCFF discounted EPS or dEPS, and sum-of-the-parts or SOP models, which are equal-weighted, averaged, and rounded to the nearest whole number to derive our 12-month price target of \$9.00.

Risk Factors: These include Clinical/Regulatory Risk, Partnership and Financial Risk, Commercial Risk, Legal and Intellectual Property Risk, and Market Share Risk.

Jason Kolbert
 jkolbert@dboralcapital.com

MARKET DATA

Rating	Buy
Price Target	\$9.00
Price	\$2.26
Average Daily Volume (000)	63
52-Week Range (\$)	\$1.12-\$2.55
Market Cap (M)	\$111
Enterprise Value (M)	\$69
Book Value	\$1.27
Dividend Yield	0.0%
Cash (M)	\$42
Qrtly Burn Rate (M)	\$(3)

ESTIMATES

	2023A	2024E	2025E
Revenue (M)	\$1.0	\$0.0	\$0.0
Total Expenses (M)	\$11	\$13	\$30
GAAP EPS	\$(0.17)	\$(0.21)	\$(0.50)

One Year Performance Chart



This report is intended for lwaki@medicinova.com. Unauthorized distribution prohibited.

Please see analyst certification and important disclosures on page 4 of this report.

Exhibit 1. MedicNova's Poster Presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal, Canada.

COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Interim Analysis Results (NCT04057898)

302

Oskarsson B, Bedlack R, Bodkins C, Dionne A, Elliott M, Genge A, Gosselin S, Goyal N, Johnston W, Maiser S, Maragakis N, Meyer JA, Rivner M, Schellenberg K, Turnbull J, Walsh A, Zinman L, Matsuda K

Mayo clinic Florida, Duke University, Indiana University, CHU de Québec-Université Laval, Montreal Neurological Institute, Université de Sherbrooke, University California Irvine, University of Alberta, Hennepin Healthcare, John Hopkins University, SUNY Upstate, University of Augusta, University of Saskatchewan, McMaster University, Lehigh Valley Health Network, Sunnybrook University and MedicNova Inc.

Background

MN-166 is an orally available small molecule that penetrates the CNS well. It inhibits macrophage migration inhibitory factor and phosphodiesterases 3, 4, and 10 with demonstrated neuroprotective action and glial cell attenuation in multiple in vitro and in vivo models. Preclinical studies have suggested that ibudilast may also act by inducing autophagy via mammalian target of rapamycin complex 1 (mTORC1)-transcription factor EB signaling in vitro, resulting in clearance of SOD1 and TAR DNA-binding protein 43 (TDP-43) aggregates. (Chen et al 2020). MN-166 has been exposed to > 900 subjects with favorable safety profile.

Based on findings from a completed Phase 1b/2a trial in ALS subjects (Oskarsson et al, NCT 02230626) we hypothesize MN-166 can slow disease progression.

Interim Analysis

Interim Analysis was conducted as pre-defined in the study protocol.

Purpose
To evaluate the correlation between Month-6 data and Month-12 data to assess the 12-month DB phase duration study design.

Analysis Population
The primary correlation analysis will be conducted on the subset of patients with both Month 6 and at least one post-Month 6 ALSFRS-R data of the full analysis set, excluding ongoing patients

Primary Analysis
Correlation analysis between Combined Assessment of Function and Survival (CAFS) scores at Month 6 and Month 12 was performed.

Sensitivity Analysis I
Modified CAFS scores at Month 6 and Month 12

Sensitivity Analysis II
Correlation analysis between change from baseline in ALSFRS-R total scores at Month 6 and Month 12 was performed

Study Objectives

Primary objective

- To evaluate the efficacy of MN-166 (ibudilast) on ALSFRS-R score and survival in ALS patients.

Major Secondary objectives

- To evaluate the efficacy on muscle strength measured by hand-held dynamometry (HHD)
- To evaluate the efficacy of MN-166 on quality of life measured by ALSAQ-5
- To evaluate the efficacy of safety and tolerability

Interim Analysis Results

A positive correlation were observed between the Month 6 and Month 12 assessments of CAFS, modified CAFS and ALSFRS-R total scores.

With sub-group analysis, positive correlation were identified in bulbar, score, fine motor score and gross motor score, but not in respiratory score. These observations support the measurement tools used in the clinical trial between timepoints.

Study Design / Method

This is a Phase 2b/3, multicenter, randomized, double-blind (12 months) placebo-controlled study followed by open-label extension phase (6 months) in ALS patients on riluzole. Patients who meet entry-criteria are randomly assigned 1 of treatment groups, MN-166 or placebo.

Major Inclusion Criteria

- Diagnosis of familial or sporadic ALS as defined by the El Escorial-Revised (2000) research diagnostic criteria for ALS [clinically definite, clinically probable, probable-laboratory-supported];
- ALS onset of ≤ 18 months from first clinical symptoms of weakness prior to screening;
- If currently using edaravone, subject should have completed the first 14 days of their initial treatment cycle prior to initiating study drug;
- A total ALSFRS-R score of at least 35 overall at screening and:
 - o a. No more than one of the 12 ALSFRS-R individual component items has a score of 1 or less at screening;
 - o For limb onset subjects, ALSFRS-R score of ≥ 3 on item #1 (speech), #2 (salivation) and #3 (swallowing);
- ALSFRS-R progression rate from onset of first symptom of weakness to the ALSFRS-R score at Screening of ≥ 0.3 points and ≤ 1 point per month calculated as: a. ALSFRS-R score at onset of first symptom of weakness (assume 48) minus ALSFRS-R score at Screening divided by number of months since onset of first symptom of weakness.
- Documented pulmonary function test (PFT) result within the last 6 months (i.e., slow vital capacity or forced vital capacity) must be ≥70% of predicted

Study Status

Currently we are enrolling in US and Canada at 17 sites. Referrals are requested. As of 15 Nov 2024, a total of 217 subjects were enrolled and 183 participants have been randomized.

Conclusion

Ongoing Phase 2/3 COMBAT-ALS study update and interim analysis results were presented.

Interim Analysis was conducted as pre-defined in the study protocol, positive correlation were observed between Month-6 and Month -12 data. These observations support the measurement tools used in the clinical trial between timepoints.

Changing the DB phase to 6 month will enhance recruitment and accelerate acquisition of results, however, it will diminish statistical power, compromise face validity, and potentially decrease probability of regulatory approval in the event of positive outcomes.

External DSMB (Data and Safety Monitoring Board) reviewed the results and made the recommendation that the trial should continue as planned and this recommendation was accepted.

Ref: Oskarsson B, Maragakis N, Bedlack RS, Goyal N, Meyer JA, Genge A, Bodkins C, Maiser S, Stoff N, Zinman L, Olvey N, Turnbull J, Brooks BR, Klonowski E, Makhay M, Yasui S, Matsuda K. MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase 1b/3 study: COMBAT-ALS study design. *Neurologist Dis Manage*. 2021 Dec;11(6):431-443. doi: 10.2217/nmd-2021-0042. Epub 2021 Nov 24. PMID: 34816762.

Source: MedicNova

MedicNova, Inc.	2023A	1Q24A	2Q24A	3Q24A	4Q24E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
Product Revenues																
US ALS									-	-	40,542	83,532	172,110	265,962	296,827	305,791
EU ALS									-	-	-	33,622	171,490	279,899	356,906	396,522
Japan ALS									-	-	-	44,275	159,613	305,317	338,667	352,315
ROW ALS									-	-	-	-	47,489	96,888	123,544	149,736
Total Product Revenues									-	-	40,542	161,430	550,702	948,065	1,115,944	1,204,364
Grant Revenue						-										
Milestone and Royalty Revenue																
Total Revenues (\$000)	1,000	-	-	-	-	-	-	-	-	-	40,542	161,430	550,702	948,065	1,115,944	1,204,364
Expenses																
COGS						-	-	-	-	-	8,108	24,215	55,070	94,807	111,594	120,436
% COGS											20%	15%	10%	10%	10%	10%
Research and Development	5,658	1,782	1,646	1,859	1,800	7,087	24,000	20,000	20,000	20,000	20,200	20,402	20,810	21,226	21,651	22,084
Selling, General and Administrative	5,242	1,354	1,400	1,450	1,500	5,704	10,000	10,100	14,000	18,000	18,180	18,362	18,545	18,731	19,105	19,488
Operating expenses	10,900	3,136	3,046	3,309	3,300	12,792	29,638	30,100	34,000	38,000	46,488	62,978	94,426	134,764	152,351	162,008
Oper. Inc. (Loss)	9,900	(3,136)	(3,046)	(3,309)	(3,300)	(12,792)	(29,638)	(30,100)	(34,000)	(38,000)	(5,947)	98,452	456,277	813,302	963,593	1,042,356
Other Income (net)	1,835	398	435	448	500	1,781	500	(40)	(40)	(10)						
Interest Income	(503)	(16)	(17)	9		(24)	-									
Interest Expense		0	(0)			(0)	-									
Financial Expenses, Net	1,332	382	418	457	500	1,757	(35)	(40)	(40)	(10)	-	-	-	-	-	-
Pretax Income	(8,568)	(2,754)	(2,628)	(2,852)	(2,800)	(11,035)	(29,673)	(30,140)	(34,040)	(38,010)	(5,947)	98,452	456,277	813,302	963,593	1,042,356
Pretax Margin																
Income Tax Benefit (Provision)	(3)	-	-	-	-	-	-	-	-	-	(595)	14,768	91,255	243,990	337,258	364,825
Tax Rate		0%	0%	0%	0%	0%	0%	0%	0%	0%	10%	15%	20%	30%	35%	35%
GAAP Net Income (loss)	(8,571)	(2,754)	(2,628)	(2,852)	(2,800)	(11,035)	(29,673)	(30,140)	(34,040)	(38,010)	(5,352)	83,684	365,021	569,311	626,335	677,531
Net Margin	NM	NM						NM	NM	NM	NM	0.52	0.66	0.60	0.56	0.56
Net loss attributable to non controlling interests	-					-	-									
GAAP-EPS	(0.17)	(0.06)	(0.05)	(0.06)	(0.05)	(0.22)	(0.50)	(0.38)	(0.40)	(0.44)	(0.06)	0.97	4.21	6.54	7.16	7.72
Non GAAP EPS (dil)	(0.17)	(0.06)	(0.05)	(0.06)	(0.05)	(0.21)	(0.50)	(0.38)	(0.40)	(0.44)	(0.06)	0.97	4.21	6.54	7.16	7.72
Wgtd Avg Shrs (Bas)	49,046	49,046	49,046	49,046	59,095	51,559	59,243	71,987	84,806	85,146	85,487	85,830	86,174	86,519	86,865	87,213
Wgtd Avg Shrs (Dil)	49,046	49,046	49,046	49,046	59,537	51,669	59,644	85,008	85,381	85,723	86,066	86,411	86,757	87,105	87,454	87,804

Source: DBoralCapital & Company reports

Important Disclosures

Analyst Certification

I, Jason Kolbert, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.

Company-Specific Disclosures

General Disclosures

This report has been produced by D. Boral Capital LLC and is for informational purposes only. It does not constitute solicitation of the sale or purchase of securities or other investments. The information contained herein is derived from sources that are believed to be reliable. Prices, numbers, and similar data contained herein include past results, estimates, and forecasts, all of which may differ from actual data. These prices, numbers, and similar data may also change without prior notification. This research report does not guarantee future performance, and the information contained herein should be used solely at the discretion and responsibility of the client. Neither D. Boral Capital nor its affiliates accept any liability or responsibility for any results in connection with the use of such information. This research report does not consider specific financial situations, needs, or investment objectives of any client, and it is not intended to provide tax, legal, or investment advice. Clients are responsible for making final investment decisions and should do so after a careful examination of all documentation delivered prior to execution, explanatory documents pertaining to listed securities, etc., prospectuses, and other relevant documents. D. Boral Capital and its affiliates may make investment decisions based on this research report. In addition, D. Boral Capital and its affiliates, as well as employees, may trade in the securities mentioned in this research report, their derivatives, or other securities issued by the same issuing companies in this research report. This research report is distributed by D. Boral Capital and/or its affiliates. The information contained herein is for client use only.

D. Boral Capital holds the copyright on this research report. Any unauthorized use or transmission of any part of this research report for any reason, whether by digital, mechanical, or any other means, is prohibited. If you have any questions, please contact your sales representative. Additional information is available upon request.

Certain company names, product and/or service names that appear in this research report are trademarks or registered trademarks of D. Boral Capital or other companies mentioned in the report.

Copyright 2024 D. Boral Capital LLC.

D. Boral Capital rating definitions are expressed as the total return relative to the expected performance of S&P 500 over a 12-month period.

BUY (B) - Total return expected to exceed S&P 500 by at least 10%

HOLD (H) - Total return expected to be in-line with S&P 500

SELL (S) - Total return expected to underperform S&P 500 by at least 10%

Distribution of Ratings/IB Services

D. Boral

Rating	Count	Percent	IB Serv./Past 12 Mos.	
			Count	Percent
BUY	46	97.87	13	28.26
HOLD	1	2.13	0	0.00
SELL	0	0.00	0	0.00

MediciNova, Inc. Rating History as of 12/05/2024

